Plc Gsk's Net Worth

$9.11 Billion

Who is Plc Gsk?

Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc., Decibel Therapeutics, Inc., Pandion Therapeutics, Inc., Nkarta, Inc., Orchard Therapeutics plc, Progyny, Inc., Fulcrum Therapeutics, Inc., Morphic Holding, Inc., BICYCLE THERAPEUTICS plc, Turning Point Therapeutics, Inc., GENOCEA BIOSCIENCES, INC., Principia Biopharma Inc., Liquidia Technologies Inc, CONSTELLATION PHARMACEUTICALS INC, Translate Bio, Inc., Spero Therapeutics, Inc., AILERON THERAPEUTICS INC, CRISPR Therapeutics AG, HTG MOLECULAR DIAGNOSTICS, INC, Theravance Biopharma, Inc., APPLIED GENETIC TECHNOLOGIES CORP, CONCERT PHARMACEUTICALS, INC., OncoMed Pharmaceuticals Inc, RESPONSE GENETICS INC, HUMAN GENOME SCIENCES INC, ChemoCentryx, Inc., Anacor Pharmaceuticals Inc, AMICUS THERAPEUTICS INC, Redpoint Bio CORP, EPIX Pharmaceuticals, Inc., CORIXA CORP, Innoviva, Inc., MEMORY PHARMACEUTICALS CORP, NUPATHE INC., QUEST DIAGNOSTICS INC, MAXYGEN INC, and 23andMe Holding Co..

SEC CIK

Plc Gsk's CIK is 0001131399

Past Insider Trading and Trends

2019 was Plc Gsk's most active year for acquiring shares with 16 total transactions. Plc Gsk's most active month to acquire stocks was the month of June. 2014 was Plc Gsk's most active year for disposing of shares, totalling 18 transactions. Plc Gsk's most active month to dispose stocks was the month of June. 2012 saw Plc Gsk paying a total of $1,317,807,537.90 for 95,334,053 shares, this is the most they've acquired in one year. In 2011 Plc Gsk cashed out on 40,156,650 shares for a total of $1,690,226,243.30, their largest year based on trade value.